Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-08-02
2005-08-02
Stockton, Laura L. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S365000, C514S364000, C514S378000, C514S411000, C546S276700, C548S450000, C548S451000, C548S181000, C548S125000, C548S247000, C548S248000
Reexamination Certificate
active
06924297
ABSTRACT:
Compounds of formula (I)and pharmaceutically acceptable derivatives thereof bind with high affinity to the EP4 receptor and are of use in the treatment or prevention of conditions such as a pain, inflammatory, immunological, bone, neurodegenerative or renal disorder.
REFERENCES:
patent: 4014899 (1977-03-01), Bowman et al.
patent: 4395417 (1983-07-01), Hall et al.
patent: 6030967 (2000-02-01), Marui et al.
patent: WO 98/25899 (1998-06-01), None
patent: WO 00/76969 (2000-12-01), None
Giblin Gerard Martin Paul
Jones Haydn Terence
Mason Andrew McMurtrie
Miller Neil Derek
Roomans Susan
Hsu Grace C.
Kinzig Charles M.
McCarthy Mary E.
SmithKline Beecham Corporation
Stockton Laura L.
LandOfFree
Naphathalene derivatives which bind to the EP4 receptor does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Naphathalene derivatives which bind to the EP4 receptor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Naphathalene derivatives which bind to the EP4 receptor will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3523430